Stock listing
Lang & Schwarz:A41ZVB Atossa Therapeutics, Inc. Aktie
German listing (Lang & Schwarz) of Atossa Therapeutics, Inc. · home listing NASDAQ:ATOS
Follow Atossa Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ATOS
$1.60 USD -0.22 (-11.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ATOS
- Day range
- $1.59 – $1.72 USDNov 20, 2026
- Volume
- 48,911 sharesNov 20, 2026
- Market cap
- $15.92M USDAt the close on Nov 20, 2026 · price × 9.98M shares outstanding
- 52-week range
- $1.59 – $14.85 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $161,555 USDMedian day 54,625 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ATOS · Home | $1.595 USD | -0.215 (-11.9%) | 48,911 | $1.72 | $1.72 | $1.59 | $1.81 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ATOS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.595 | -0.215 | -11.9% | $1.72 | $1.72 | $1.59 | 48,911 | |
| $1.81 | -0.09 | -4.7% | $1.85 | $1.92 | $1.79 | 43,783 | |
| $1.90 | -0.03 | -1.6% | $1.90 | $2.003 | $1.842 | 46,482 | |
| $1.93 | -0.03 | -1.5% | $1.98 | $2.09 | $1.86 | 69,553 | |
| $1.96 | +0.02 | +1.0% | $1.91 | $2.00 | $1.85 | 56,354 | |
| $1.94 | -0.09 | -4.4% | $2.03 | $2.059 | $1.81 | 91,448 | |
| $2.03 | -0.11 | -5.1% | $2.17 | $2.189 | $2.03 | 41,464 | |
| $2.14 | +0.01 | +0.5% | $2.12 | $2.31 | $2.076 | 55,558 | |
| $2.13 | +0.01 | +0.5% | $2.15 | $2.20 | $2.112 | 40,134 | |
| $2.12 | +0.10 | +5.0% | $1.99 | $2.19 | $1.99 | 34,371 | |
| $2.02 | -0.10 | -4.7% | $2.12 | $2.121 | $1.98 | 75,033 | |
| $2.12 | -0.21 | -9.0% | $2.33 | $2.35 | $2.10 | 70,186 | |
| $2.33 | +0.03 | +1.3% | $2.31 | $2.35 | $2.27 | 26,078 | |
| $2.30 | +0.13 | +6.0% | $2.21 | $2.40 | $2.205 | 65,998 | |
| $2.17 | -0.06 | -2.7% | $2.25 | $2.43 | $2.14 | 32,903 | |
| $2.23 | -0.14 | -5.9% | $2.35 | $2.375 | $2.22 | 68,006 | |
| $2.37 | -0.01 | -0.4% | $2.38 | $2.425 | $2.36 | 29,410 | |
| $2.38 | -0.07 | -2.9% | $2.44 | $2.628 | $2.37 | 24,830 | |
| $2.45 | -0.15 | -5.8% | $2.58 | $2.58 | $2.40 | 35,077 | |
| $2.60 | -0.12 | -4.4% | $2.74 | $2.85 | $2.60 | 77,024 | |
| $2.72 | +0.19 | +7.5% | $2.49 | $2.77 | $2.46 | 90,656 | |
| $2.53 | -0.01 | -0.4% | $2.53 | $2.585 | $2.38 | 189,632 | |
| $2.54 | -0.02 | -0.8% | $2.54 | $2.67 | $2.51 | 36,755 | |
| $2.56 | -0.35 | -12.0% | $2.66 | $2.76 | $2.51 | 80,522 | |
| $2.91 | +0.26 | +9.8% | $2.59 | $2.95 | $2.51 | 104,625 | |
| $2.65 | -0.13 | -4.7% | $2.78 | $3.12 | $2.53 | 227,027 | |
| $2.78 | +0.22 | +8.6% | $2.52 | $2.81 | $2.45 | 238,706 | |
| $2.56 | +0.171 | +7.2% | $2.35 | $2.60 | $2.30 | 71,414 | |
| $2.389 | -0.051 | -2.1% | $2.44 | $2.53 | $2.335 | 81,419 | |
| $2.44 | +0.02 | +0.8% | $2.45 | $2.74 | $2.12 | 265,612 | |
| $2.42 | -0.04 | -1.6% | $2.46 | $2.478 | $2.385 | 101,012 | |
| $2.46 | +0.01 | +0.4% | $2.41 | $2.49 | $2.41 | 19,070 | |
| $2.45 | 0.00 | 0.0% | $2.46 | $2.54 | $2.43 | 54,625 | |
| $2.45 | +0.11 | +4.7% | $2.38 | $2.50 | $2.341 | 53,315 | |
| $2.34 | +0.07 | +3.1% | $2.23 | $2.379 | $2.17 | 74,271 | |
| $2.27 | +0.32 | +16.4% | $1.96 | $2.30 | $1.96 | 113,600 | |
| $1.95 | -0.04 | -2.0% | $1.99 | $2.15 | $1.95 | 67,768 | |
| $1.99 | +0.03 | +1.5% | $2.06 | $2.16 | $1.96 | 83,318 | |
| $1.96 | +0.06 | +3.2% | $1.905 | $2.04 | $1.82 | 152,932 | |
| $1.90 | -0.15 | -7.3% | $2.06 | $2.065 | $1.89 | 77,843 | |
| $2.05 | -0.13 | -6.0% | $2.15 | $2.22 | $2.05 | 37,461 | |
| $2.18 | -0.08 | -3.5% | $2.25 | $2.26 | $2.15 | 37,187 | |
| $2.26 | +0.01 | +0.4% | $2.25 | $2.43 | $2.25 | 129,526 | |
| $2.25 | +0.03 | +1.4% | $2.25 | $2.39 | $2.25 | 67,169 | |
| $2.22 | -0.18 | -7.5% | $2.37 | $2.38 | $2.22 | 39,755 | |
| $2.40 | -0.02 | -0.8% | $2.42 | $2.43 | $2.37 | 33,288 | |
| $2.42 | +0.05 | +2.1% | $2.39 | $2.48 | $2.39 | 45,776 | |
| $2.37 | -0.11 | -4.4% | $2.475 | $2.49 | $2.37 | 43,779 | |
| $2.48 | -0.03 | -1.2% | $2.53 | $2.555 | $2.45 | 35,039 | |
| $2.51 | +0.17 | +7.3% | $2.36 | $2.54 | $2.36 | 60,410 | |
| $2.34 | -0.06 | -2.5% | $2.36 | $2.61 | $2.33 | 47,238 | |
| $2.40 | -0.115 | -4.6% | $2.54 | $2.54 | $2.40 | 24,800 | |
| $2.515 | -0.005 | -0.2% | $2.49 | $2.587 | $2.445 | 41,370 | |
| $2.52 | -0.01 | -0.4% | $2.51 | $2.60 | $2.50 | 28,028 | |
| $2.53 | +0.07 | +2.8% | $2.50 | $2.60 | $2.46 | 56,692 | |
| $2.46 | +0.04 | +1.7% | $2.40 | $2.51 | $2.39 | 44,771 | |
| $2.42 | -0.08 | -3.2% | $2.48 | $2.50 | $2.317 | 92,004 | |
| $2.50 | -0.08 | -3.1% | $2.57 | $2.59 | $2.50 | 53,194 | |
| $2.58 | -0.06 | -2.3% | $2.62 | $2.62 | $2.50 | 49,003 | |
| $2.64 | -0.01 | -0.4% | $2.64 | $2.69 | $2.585 | 23,115 | |
| $2.65 | -0.03 | -1.1% | $2.66 | $2.70 | $2.61 | 26,301 | |
| $2.68 | +0.04 | +1.5% | $2.62 | $2.69 | $2.58 | 49,690 | |
| $2.64 | +0.10 | +3.9% | $2.56 | $2.65 | $2.45 | 57,149 | |
| $2.54 | -0.05 | -1.9% | $2.59 | $2.62 | $2.51 | 25,656 | |
| $2.59 | -0.05 | -1.9% | $2.62 | $2.62 | $2.44 | 70,954 |
Splits
3 splits since 2016 · NASDAQ:ATOS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation | |
| 1-for-12 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- Lang & Schwarz:A41ZVB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 29 slides
Latest news
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Nov 10, 2026
Closed $2.14 (+0.5%) on Nov 10, 2026
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
Oct 19, 2026
Closed $2.56 (-12.0%) on Oct 19, 2026
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
Oct 9, 2026
Closed $2.44 (+0.8%) on Oct 9, 2026
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Sep 29, 2026
Closed $1.99 (+1.5%) on Sep 29, 2026
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
Jul 28, 2026
Closed $2.42 (+2.3%) on Jul 28, 2026
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
Jul 21, 2026
Closed $2.40 (-3.6%) on Jul 21, 2026
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
Jun 12, 2026
Closed $2.35 (-4.5%) on Jun 15, 2026
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
Jun 11, 2026
Closed $2.59 (-41.3%) on Jun 11, 2026
Atossa Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 29 in the last 12 months · 186 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 4 calls with a replay · 4 with a transcript · latest Mar 25, 2025
- Decks
- 9 decks · latest September 2026
Where Atossa Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ATOS · Home listing | NASDAQ | United States | USD |
| BMV:ATOS | BMV | Mexico | MXN |
| Tradegate:YAG | Tradegate | Germany | EUR |
| gettex:YAG | gettex | Germany | EUR |
| LS Exchange:A2JJ99 | LS Exchange | Germany | EUR |
| BIVA:ATOS | BIVA | Mexico | MXN |
| BOATS:ATOS | BOATS | United States | USD |
| Lang & Schwarz:A2JJ99 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A41ZVB | LS Exchange | Germany | EUR |
| Dusseldorf:YAG | Dusseldorf | Germany | USD |
| Frankfurt:YAG | Frankfurt | Germany | EUR |
| Lang & Schwarz:A41ZVB · This page | Lang & Schwarz | Germany | EUR |
| Munich:YAG | Munich | Germany | EUR |
Valuation
Price/book 0.7× against a median of 1.7×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$4.66M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.87
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.76M | US$15.67M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| Lipocine Inc. · NASDAQ:LPCN | US$16.39M | −US$5.07M | n/a | −1.4× | n/a | 0.8× | −249.2% | 0.0× | 1.18 |
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.11M | US$10.42M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| Median of the others | US$16.25M | US$11.52M | 3.7× | −0.1× | 1.7× | −213.8% | 0.0× | 1.18 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.56 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Steven Quay | Chief Executive Officer |
| Mark Daniel | Chief Financial Officer |
| Janet R. Rea | Senior Vice President, R&D |
Events
Calls
| Call | When | Status |
|---|---|---|
| Atossa Therapeutics (NASDAQ:ATOS) Q4 2024 Earnings Call | Tue, Mar 25, 2025 · 8:30 AM ET | Replay |
| Atossa Therapeutics (NASDAQ:ATOS) Q4 2023 Earnings Call | Tue, Mar 26, 2024 · 9:00 AM ET | Replay |
| Atossa Therapeutics (NASDAQ:ATOS) Q3 2023 Earnings Call | Thu, Oct 26, 2023 · 9:00 AM ET | Replay |
| Atossa Therapeutics (NASDAQ:ATOS) Q2 2023 Earnings Call | Mon, Aug 14, 2023 · 9:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +0.5% |
| Q2 2026 | Aug 7, 2026 | −2.1% |
| Q1 2026 | May 8, 2026 · Before open | −1.2% |
| Q4 2025 | Mar 26, 2026 | −12.9% |
| Q3 2025 | Nov 12, 2025 · Before open | −1.7% |
| Q2 2025 | Aug 12, 2025 · Before open | +1.2% |
| Q1 2025 | May 13, 2025 · Before open | +6.3% |
| Q4 2024 | Mar 31, 2025 · Before open | −3.4% |
| Q3 2024 | Nov 12, 2024 · Before open | −7.4% |
| Q2 2024 | Aug 12, 2024 · Before open | +6.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | −2.0% |
| Q4 2023 | Mar 28, 2024 · Before open | −1.6% |
| Q3 2023 | Nov 13, 2023 · Before open | −0.6% |
| Q2 2023 | Aug 14, 2023 · Before open | −8.3% |
| Q1 2023 | May 15, 2023 · Before open | +0.3% |
| Q4 2022 | Mar 22, 2023 · After close | −5.1% |
| Q3 2022 | Nov 7, 2022 · After close | −4.4% |
| Q2 2022 | Aug 8, 2022 · After close | −6.7% |
| Q1 2022 | May 9, 2022 · After close | +3.6% |
| Q4 2021 | Feb 28, 2022 · After close | +6.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 29 slides | September 2026 |
| Atossa Genetics — Corporate Update (September 2018) | Corporate update | 25 slides | Sep 13, 2018 |
| Atossa Genetics — IPO Roadshow (May 2018) | IPO roadshow | 30 slides | May 16, 2018 |
| Atossa Genetics — Investor Presentation (February 2018) | Investor deck | 31 slides | Feb 21, 2018 |
| Atossa Genetics — Corporate Update (February 2018) | Corporate update | 31 slides | Feb 1, 2018 |
| Atossa Genetics — Corporate Update (October 2017) | Corporate update | 51 slides | Oct 25, 2017 |
| Atossa Genetics — Corporate Update (September 2017) | Corporate update | 34 slides | Sep 14, 2017 |
| Atossa Genetics — Investor Presentation (July 2016) | Investor deck | 21 slides | Jul 27, 2016 |
| Atossa Genetics — Investor Presentation (January 2015) | Investor deck | 19 slides | Jan 15, 2015 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock (or common stock equivalents) with Series A and Series B warrants Closed: US$4.5M raised · Series A and Series B warrants exercisable six months after issuance; Series A expire… · Rodman & Renshaw LLC Dealers: Rodman & Renshaw LLC (lead) Use of proceeds: Clinical development of product candidates, working capital and general corporate purposes | Jun 12, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as ATOSSA GENETICS INC. Priced at US$5.00 a share on Nov 7, 2012.
- Price
- US$5.00 a share
- Shares offered
- 800,000 shares of common stock
- Offering size
- US$4 million
- Underwriters' option
- Up to 120,000 more shares
- Underwriter
- DAWSON JAMES SECURITIES, INC.
- Shares delivered
- On or about Nov 13, 2012
Steps
| Step | When |
|---|---|
| Filed publicly | Feb 14, 2012 |
| Amended 12 times | Newest Nov 6, 2012 |
| Shares registered with an exchange | Jul 24, 2012 |
| Declared effective by the SEC | Nov 7, 2012 |
| Final prospectus, with the price | Nov 9, 2012 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 9, 2012 |
| CERTNAS · Nasdaq's certificate of listing | Nov 7, 2012 |
| EFFECT · Notice that a registration is effective | Nov 7, 2012 |
| S-1/A · Registration statement, amended | Nov 6, 2012 |
| CORRESP · Letter to the SEC | Nov 5, 2012 |
| CORRESP · Letter to the SEC | Nov 5, 2012 |
| CORRESP · Letter to the SEC | Oct 26, 2012 |
| CORRESP · Letter to the SEC | Oct 26, 2012 |
| S-1/A · Registration statement, amended | Oct 25, 2012 |
| CORRESP · Letter to the SEC | Oct 19, 2012 |
All 40 filings
Open IPO · From the cover of the final prospectus (424B4) filed Nov 9, 2012
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 16.0K | 17.0K | 23.0K | 8.00K | 23.0K | 46.6K | 52.8K | 44.2K | 129.0K | 303.5K |
| Gross profit | -16.0K | -17.0K | -23.0K | -8.00K | -23.0K | -46.6K | -52.8K | -44.2K | -129.0K | -303.5K |
| Research and development | 21.2M | 14.1M | 17.3M | 15.1M | 9.21M | 6.61M | 6.65M | 4.21M | 2.33M | 770.4K |
| Selling, general and administrative | 16.0M | 13.5M | 14.0M | 12.6M | 11.3M | 8.00M | 10.6M | 7.22M | 4.86M | 6.48M |
| Operating income | -37.1M | -27.6M | -31.4M | -27.7M | -20.5M | -14.6M | -17.3M | -11.4M | -7.65M | -7.97M |
| Depreciation and amortization | 16.0K | 17.0K | 23.0K | 8.00K | 23.0K | 47.0K | 52.8K | 44.2K | 129.0K | 303.5K |
| EBITDA | -37.1M | -27.6M | -31.4M | -27.7M | -20.5M | -14.6M | -17.2M | -11.4M | -7.52M | -7.67M |
| Interest expense | 8.00K | 85.0K | 938.8K | 0 | 0 | 192.8K | 0 | |||
| Income before tax | -34.8M | -25.5M | -30.1M | -27.0M | -20.6M | -17.8M | -17.2M | -11.4M | -8.12M | -6.37M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.76M |
| Net income | -34.8M | -25.5M | -30.1M | -27.0M | -20.6M | -17.8M | -17.2M | -11.4M | -8.12M | -6.37M |
| Earnings per share, basic | -4.04 | -3.04 | -0.24 | -0.21 | -0.18 | -1.97 | -2.03 | -5.50 | -10.97 | -2.16 |
| Earnings per share, diluted | -4.04 | -3.04 | -0.24 | -0.21 | -0.18 | -1.97 | -2.03 | -5.50 | -10.97 | -2.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 41.3M | 71.1M | 88.5M | 110.9M | 136.4M | 39.6M | 12.6M | 10.4M | 7.22M | 3.03M |
| Short-term investments | 55.0K | 55.0K | ||||||||
| Receivables | -1.43M | 743.0K | 1.07M | 634.9K | 739.7K | 518.1K | 358.3K | 194.3K | ||
| Inventory | 1.49M | 5.25M | 2.60M | 1.92M | 972.3K | 619.8K | 305.9K | 0 | ||
| Current assets | 45.6M | 74.5M | 92.2M | 118.2M | 141.2M | 42.8M | 14.3M | 11.5M | 7.90M | 3.25M |
| Property, plant and equipment | 20.0K | 21.0K | 34.4K | 54.5K | 11.5K | 55.1K | ||||
| Goodwill | 0 | 0 | ||||||||
| Total assets | 47.6M | 76.4M | 96.3M | 123.5M | 141.3M | 42.8M | 14.5M | 11.7M | 8.16M | 4.14M |
| Accounts payable | 4.29M | 679.0K | 806.0K | 2.96M | 1.72M | 1.59M | 293.2K | 353.3K | 334.9K | 254.3K |
| Current liabilities | 8.26M | 4.97M | 5.24M | 5.57M | 3.13M | 15.7M | 1.32M | 2.92M | 1.23M | 1.05M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 18.1K | 50.5K | ||||||||
| Total liabilities | 8.26M | 4.97M | 5.24M | 5.57M | 3.13M | 15.7M | 1.33M | 2.92M | 1.23M | 1.05M |
| Shareholders' equity | 39.4M | 71.5M | 91.0M | 118.0M | 138.1M | 27.2M | 13.2M | 8.81M | 6.94M | 3.10M |
| Shares outstanding | 8.61M | 8.61M | 125.3M | 126.6M | 126.6M | 47.5M | 9.13M | 5.85M | 2.65M | 3.79M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -29.8M | -21.0M | -20.9M | -20.8M | -16.5M | -11.6M | -9.13M | -8.96M | -6.59M | -5.37M |
| Capital spending | -23.0K | -19.0K | -14.0K | -27.0K | -9.00K | -9.00K | -7.63K | -110.9K | -110.9K | -9.21K |
| Free cash flow | -29.8M | -21.0M | -21.0M | -20.8M | -16.5M | -11.6M | -9.14M | -9.07M | -6.59M | -5.38M |
| Cash from investing | -23.0K | -19.0K | -14.0K | -4.73M | -9.00K | -9.00K | -7.63K | -110.9K | -110.9K | -9.21K |
| Cash from financing | 0 | 3.67M | -1.48M | 0 | 113.3M | 38.6M | 11.3M | 12.3M | 10.8M | 4.70M |
| Dividends paid | -4.50M | 0 | 0 | |||||||
| Share buybacks | 0 | -1.48M | 0 | -573 | 9.61M | 11.3M | 12.3M | 10.0M | 4.70M | |
| Change in cash | -29.8M | -17.4M | -22.4M | -25.5M | 96.8M | 27.0M | 2.20M | 3.22M | 4.19M | -687.9K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 9, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 8-K · Current report | Sep 18, 2026 | Current report | SEC |
| 8-K · Current report | Aug 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 424B5 · Prospectus | Jun 12, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 11, 2026 | Material contract | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 8-K · Current report | May 8, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Apr 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 30, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 30, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 20, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 20, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Feb 20, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 17, 2026 | Current report | SEC |
| 8-K · Current report | Feb 11, 2026 | Current report | SEC |
| 4/A · Change in ownership, amended | Jan 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 26, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 9, 2026 | Results | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Dec 22, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 12, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 14, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 26, 2025 | Current report | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| 8-K · Current report | Aug 21, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 8-K · Current report | May 9, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 26, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 26, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| 8-K · Current report | Mar 12, 2025 | Current report | SEC |
| 8-K · Current report | Feb 24, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2025 | Current report | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 8-K · Current report | Nov 19, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 19, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Jul 2, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 24, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | May 23, 2024 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | May 21, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 21, 2024 | Other filings | SEC |
| DEL AM | May 14, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 13, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| ARS · Annual report to shareholders | May 10, 2024 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | May 10, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 11, 2024 | Insider trade | SEC |
| 8-K/A · Current report, amended | Apr 1, 2024 | Results | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 1, 2024 | Results | SEC |
| 8-K · Current report | Mar 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 12, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 15, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 15, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 8-K · Current report | Nov 9, 2023 | Management or board change | SEC |
| 3 · Initial statement of ownership | Oct 16, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 6, 2023 | Management or board change | SEC |
| 8-K · Current report | Sep 28, 2023 | Current report | SEC |
| 8-K · Current report | Aug 30, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 8-K · Current report | Jul 13, 2023 | Current report | SEC |
| 8-K · Current report | Jun 28, 2023 | Current report | SEC |
| 8-K · Current report | Jun 23, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 1, 2023 | Management or board change | SEC |
| 8-K · Current report | May 22, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| 4 · Change in ownership | May 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2023 | Insider trade | SEC |
| 8-K · Current report | May 4, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 26, 2023 | Current report | SEC |
| 8-K · Current report | Apr 4, 2023 | Current report | SEC |
| ARS · Annual report to shareholders | Mar 30, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 30, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Mar 22, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 22, 2023 | Results | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 4 · Change in ownership | Mar 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2022 | Results | SEC |
| 8-K · Current report | Oct 7, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2022 | Results | SEC |
| SC 13G · Big-stake notice | Jul 8, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Jul 7, 2022 | Current report | SEC |
| 8-K · Current report | Jul 1, 2022 | Current report | SEC |
| 8-K · Current report | Jun 6, 2022 | Current report | SEC |
| 4 · Change in ownership | May 16, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2022 | Insider trade | SEC |
| 8-K · Current report | May 16, 2022 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2022 | Results | SEC |
| DEF 14A · Proxy statement | Apr 11, 2022 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 1, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | Feb 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2022 | Insider trade | SEC |
| 10-K · Annual report | Feb 28, 2022 | Annual report | SEC |
| 8-K · Current report | Feb 28, 2022 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 9, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 4, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 13, 2022 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 15, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 15, 2021 | Results | SEC |
| 8-K · Current report | Oct 6, 2021 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Sep 14, 2021 | Meeting notice | SEC |
| 8-K · Current report | Sep 8, 2021 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 13, 2021 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2021 | Results | SEC |
| DEF 14A · Proxy statement | Aug 9, 2021 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 29, 2021 | Meeting notice | SEC |
| 4 · Change in ownership | Jul 7, 2021 | Insider trade | SEC |
| 8-K · Current report | May 18, 2021 | Management or board change | SEC |
| 4 · Change in ownership | May 18, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2021 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2021 | Results | SEC |
This page holds 200 of 643 filings. Open Filings
Cap table
Built by 6ix from Atossa Therapeutics, Inc.’s releases · as of Jul 31, 2026
- Common shares
- 9,979,298
- Fully diluted
- 9,979,298
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 9,979,298 | Jul 31, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Jul 31, 2026 | 9,979,298 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard I. Steinhart Other companies: BioXcel Therapeutics, Inc. (Senior Vice President and Chief Financial Officer · Since at least Mar 7, 2018); Actinium Pharmaceuticals, Inc. (Delaware) (Director · Since at least Nov 8, 2013); MELA Sciences Inc (Chief Financial Officer · May 14, 2010 – Aug 5, 2013 · Past); TG Therapeutics, Inc. (Director · Mar 25, 2008 – Mar 3, 2010 · Past) | Director · Since at least Mar 1, 2014 |
| Christopher Benjamin Other companies: Quantum Materials Corp (Director · Jun 30, 2011 – Oct 2, 2015 · Past) | Chief Financial Officer · Nov 7, 2012 – Nov 7, 2012 · Past |
| Gregory L Weaver Other companies: Altimmune, Inc. (Chief Financial Officer · Since at least Nov 11, 2024) | Former EVP, CFO, & Director, Director · May 17, 2019 – Nov 15, 2023 · Past |
| Kyle Guse Other companies: Plus Therapeutics, Inc. (Director · Since at least Apr 18, 2025) | CFO, Gen Counsel and Secretary · Jan 4, 2013 – Mar 2, 2023 · Past |
| Ben R Chen | Sr. VP of Glob. Reg. Affairs · Apr 1, 2014 – Apr 1, 2014 · Past |
| Christopher S Destro | SVP, Sales and Marketing · May 6, 2014 – Mar 16, 2015 · Past |
| Claudia Lopez | Vice President, Clinical Product Development · Nov 5, 2024 – Nov 5, 2026 · Past |
| Heather Rees | Chief Financial Officer · Oct 6, 2023 – May 15, 2025 · Past |
| H Lawrence Remmel | Director · Since at least Nov 7, 2012 |
| Janet R. Rea | Senior Vice President, R&D · Since at least Nov 12, 2025 |
All 18 people
| Person | Seat |
|---|---|
| Jonathan Finn | Director · Since at least Nov 8, 2023 |
| Mark Daniel | Chief Financial Officer · Since at least Oct 14, 2025 |
| Peter J Carbonaro | Sr. Vice President, Operations · May 6, 2014 – May 6, 2014 · Past |
| Scott Youmans | Chief Operating Officer · Sep 1, 2015 – Sep 1, 2015 · Past |
| Shu-Chih Chen | Director · Since at least Nov 7, 2012 |
| Stephen J Galli | Director · Since at least Nov 7, 2012 |
| Steven Quay | Chief Executive Officer · Since at least Nov 7, 2012 |
| Tessa Cigler | Director · Since at least Mar 9, 2024 |
Log in to ask 6ix AI your own questions about Atossa Therapeutics, Inc.